Swedish Orphan Biovitrum AB (SOBI) is a pharmaceutical company that specializes in the development and production of medical treatments for rare diseases. Their flagship product, SYNAGIS, is a prescription medication used to prevent severe lung disease caused by respiratory syncytial virus (RSV) in premature infants and children with certain medical conditions. SYNAGIS contains disease-fighting proteins called antibodies and is administered through injections. SOBI is committed to providing support programs, resources, and financial assistance to parents and caregivers of vulnerable babies.
SOBI, formerly owned by AstraZeneca, is dedicated to improving the lives of patients by developing innovative therapies and treatments. With a focus on rare diseases, they strive to address unmet medical needs and provide effective solutions. SYNAGIS, their leading product, offers protection against RSV disease, a common respiratory infection in infants. SOBI's mission is to ensure the health and well-being of vulnerable babies by offering safe and effective treatments, backed by extensive research and clinical trials.
Generated from the website